Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Stopped The entire drug development program for this molecule was sold to another company.

Conditions

• Parkinson's Syndrome

Interventions

• DRUG: NAV5001

Sponsor

Navidea Biopharmaceuticals